What changed in Agilent Technologies, Inc.'s latest annual report
In the year ended 31 Oct 2025, Agilent Technologies, Inc.'s revenue rose 6.7% to USD 6.95bn, from USD 6.51bn; net income rose 1.1% to USD 1.30bn, from USD 1.29bn; cash and cash equivalents rose 34.6% to USD 1.79bn, from USD 1.33bn.
Year ended 31 Oct 2025. Source: 10-K filed 22 Dec 2025, read it on SEC EDGAR.
USD 6.51bn to USD 6.95bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 6.51bn | 6.95bn | Up 6.7% |
| Net income | 1.29bn | 1.30bn | Up 1.1% |
| Total assets | 11.85bn | 12.73bn | Up 7.4% |
| Total liabilities | 5.95bn | 5.99bn | Up 0.6% |
| Long-term debt | 3.35bn | 3.05bn | Down 8.8% |
| Cash and cash equivalents | 1.33bn | 1.79bn | Up 34.6% |
| Shareholders' equity | 5.90bn | 6.74bn | Up 14.3% |
Questions people ask
Did Agilent Technologies, Inc.'s revenue grow last year?
Revenue grew 6.7%, from USD 6.51bn to USD 6.95bn in the year ended 31 Oct 2025.
Is Agilent Technologies, Inc. profitable?
Yes. Net income was USD 1.30bn in the year ended 31 Oct 2025. The year before: USD 1.29bn.
How much cash and debt does Agilent Technologies, Inc. have?
At its latest year end (31 Oct 2025), Agilent Technologies, Inc. reported cash and cash equivalents of USD 1.79bn and long-term debt of USD 3.05bn.
Where do these numbers come from?
From Agilent Technologies, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Agilent Technologies, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Laboratory Analytical Instruments companies
- Waters CorporationCash and cash equivalents up 80.7%
- Illumina, Inc.Shareholders' equity up 14.7%
- Mettler-Toledo International Inc.Total assets up 14.6%
- Revvity, IncCash and cash equivalents down 20.9%
- Avantor, Inc.Cash and cash equivalents up 39.5%
- 10x Genomics, Inc.Total liabilities up 17.5%
- Bio-Rad Laboratories, Inc.Shareholders' equity up 13.5%